Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma

BACKGROUND: Trabectedin is reported to be particularly effective against translocation-related sarcoma. Recently, a randomized phase 2 study in patients with translocation-related sarcomas unresponsive or intolerable to standard chemotherapy was conducted, which showed clinical benefit of trabectedi...

Descripción completa

Detalles Bibliográficos
Autores principales: Morioka, Hideo, Takahashi, Shunji, Araki, Nobuhito, Sugiura, Hideshi, Ueda, Takafumi, Takahashi, Mitsuru, Yonemoto, Tsukasa, Hiraga, Hiroaki, Hiruma, Toru, Kunisada, Toshiyuki, Matsumine, Akihiko, Susa, Michiro, Nakayama, Robert, Nishimoto, Kazumasa, Kikuta, Kazutaka, Horiuchi, Keisuke, Kawai, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946242/
https://www.ncbi.nlm.nih.gov/pubmed/27418251
http://dx.doi.org/10.1186/s12885-016-2511-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946242/
https://www.ncbi.nlm.nih.gov/pubmed/27418251
http://dx.doi.org/10.1186/s12885-016-2511-y

Ejemplares similares